{"title":"Editor's Highlights—January 2025","authors":"Lajos Kemény","doi":"10.1111/ijd.17604","DOIUrl":null,"url":null,"abstract":"<p>Immune-mediated inflammatory skin diseases (IMIDs) frequently result in chronic and debilitating health conditions that significantly diminish patients' quality of life. In the past 10 years, we have seen a huge breakthrough in treating IMIDs by blocking cytokines or cytokine receptors through monoclonal antibodies and by blocking the signaling pathway using Janus kinase (JAK) inhibitors. Nowadays, an increasing number of patients with different immune-mediated skin diseases are being treated with systemic and topical JAK inhibitors. Dermatologists frequently use these new medications in an off-label way to treat various skin diseases. Thus, in the January issue of the Journal, we show the efficacy of JAK inhibitors in treating erythema nodosum leprosum, silicone-induced foreign body reactions in a patient with chronic graft-versus-host disease, but also cover the potential side effects of JAK inhibitors in treating skin diseases.</p>","PeriodicalId":13950,"journal":{"name":"International Journal of Dermatology","volume":"64 1","pages":"3-4"},"PeriodicalIF":3.5000,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ijd.17604","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Immune-mediated inflammatory skin diseases (IMIDs) frequently result in chronic and debilitating health conditions that significantly diminish patients' quality of life. In the past 10 years, we have seen a huge breakthrough in treating IMIDs by blocking cytokines or cytokine receptors through monoclonal antibodies and by blocking the signaling pathway using Janus kinase (JAK) inhibitors. Nowadays, an increasing number of patients with different immune-mediated skin diseases are being treated with systemic and topical JAK inhibitors. Dermatologists frequently use these new medications in an off-label way to treat various skin diseases. Thus, in the January issue of the Journal, we show the efficacy of JAK inhibitors in treating erythema nodosum leprosum, silicone-induced foreign body reactions in a patient with chronic graft-versus-host disease, but also cover the potential side effects of JAK inhibitors in treating skin diseases.
期刊介绍：
Published monthly, the International Journal of Dermatology is specifically designed to provide dermatologists around the world with a regular, up-to-date source of information on all aspects of the diagnosis and management of skin diseases. Accepted articles regularly cover clinical trials; education; morphology; pharmacology and therapeutics; case reports, and reviews. Additional features include tropical medical reports, news, correspondence, proceedings and transactions, and education.
The International Journal of Dermatology is guided by a distinguished, international editorial board and emphasizes a global approach to continuing medical education for physicians and other providers of health care with a specific interest in problems relating to the skin.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
